RSSL, a pharmaceutical contract research organization, has announced a new Innovation Hub—a dedicated platform to help small- and medium-sized biotech organizations de-risk and accelerate the development of cutting-edge products.
RSSL’s Innovation Hub aims to be a supportive ecosystem for early-stage biotech companies, providing a range of tailored services to help them navigate their journeys from concept to commercialization.
According to the company, by working with RSSL, clients can access on-site commercial laboratory space, with equipment and instrumentation available for use. They will also be able to benefit from RSSL’s expertise, project management experience, and network of industry contacts to support their product development.
About the Platform
The platform comprises four different models that will allow clients to collaborate with RSSL on a flexible basis depending on their needs. For each model, clients will have a dedicated account manager to oversee operations and serve as their main point of contact. The four models include:
- Innovate: Clients have access to laboratory space and equipment, with the option to utilize RSSL’s range of services as required.
- Forge: Clients have access to laboratory space, equipment, and services, plus consultancy in key areas such as training and regulatory compliance.
- Launchpad: A model designed for clients looking for support with commercial development.
- 360: A model providing clients with full-service support across the entire development pipeline, from initial concept to commercial manufacturing.
The launch of RSSL’s Innovation Hub is a key component of its long-term expansion strategy that will see the company implement several initiatives to increase its operational capacity and breadth of services. These initiatives will build on the recent opening of its new analytical testing facility, which has added 26,000 sq. ft. of working laboratory space. They will also play a crucial role in supporting its plans to double the number of members within its scientific team over the next three years.
Jacinta George, Managing Director, RSSL said: “Our goal is to drive vital research and support innovation across the entire life science sector. With the new Innovation Hub, we are providing start-ups, spin-outs, and other early-stage biotech organizations with dedicated laboratory space and specialist expertise to fast-track their development programs. We know how difficult it can be for emerging companies to access commercial facilities, so we’re incredibly proud to be providing our support. Through this collaboration, we’re excited to help them develop the next wave of ground-breaking products — from life-changing cell and gene therapies to next-generation vaccines and medical devices.”
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
